Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron vs anticholinergic therapy for overactive bladder
IRCT20230514058174N1Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of mirabegron in overactive bladder (OAB) and urinary incontinence (UI) (2 arms), sponsored by Tehran University of Medical Sciences. Started Feb 2026; status: recruiting.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)urinary incontinence (UI)
Beyond the preview
Go deeper on IRCT20230514058174N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230514058174N1.